Position in SVTR
Snapshot 2026-11-04- Startup SignalsRankedof 2,311↓44
- Life SciencesRankedof 244↓2
- AutomationRankedof 214↓5
About
Phyraxis AI (Shanghai Feirui Kesi Intelligent Technology Co., Ltd.), founded in August 2026 in Shanghai, builds physical AI for science: robots plus AI that close the loop of task understanding, execution, process recording, quality verification and model training in real life-science labs, via a protocol compiler, robot/instrument adaptation layer, execution-evidence ledger, quality verifier and SOP evolution.
Funding history
- 2026-09-18Strategic数百万元级人民币
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Phyraxis AI
Physical AI for life science experiments: robots and AI forming a closed loop of experimental task understanding, execution, process recording…
Strategic · 2026-09
—
United States
BusinessLatest roundTotal raisedDate- Opentrons
Pipetting automation robots and software for life science labs, plus OpentronsAI for generating protocols from natural language.
Series D+ · 2026-10
— - Lila Sciences
Uses AI to analyze data, design experiments and direct robotic systems to carry out experiments in the life sciences, chemistry and materials science
Series A · $550M · 2025-10
$550M - Cheiron
AI-native "drug program operating system" for biopharma teams that models drug R&D programs on a life sciences knowledge graph
Seed · $8M · 2026-07
$8M
China
BusinessLatest roundTotal raisedDateEurope
BusinessLatest roundTotal raisedDate- Vitestro
Developed a device that integrates AI with ultrasound imaging and robotics to automate blood collection
Series B · $120M · 2026-03
$120M - LabGenius
Machine learning and robotic automation to discover and optimize therapeutic antibodies
Series B · $45M · 2024-05
$45M - IgniteData
Automatically transfers patient data from electronic health records to clinical trial electronic data capture systems
Seed · $8M · 2024-06
$8M
Other / unspecified
BusinessLatest roundTotal raisedDate- Intrepid Labs
Autonomous labs combining AI, robotics and chemistry to accelerate drug compound formulation
Seed · $11M · 2025-05
$11M - 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Scispot
Lab operating system for biotech and pharmaceutical labs
Series A · $10M · 2026-06
$10M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.